Today, we announced a new Licensing and Research Partnership with 3B Pharmaceuticals GmbH to advance a first-in-class #Alpha #Radioligand #Therapies (#ART) for the treatment of solid tumors. ARTBIO will develop this novel program, starting with human imaging. This first-in-class radiopharma target has the potential to impact several solid tumor indications in which patients have limited and sub-optimal options. This #partnership expands ARTBIO's pipeline and combines our AlphaDirect? platform for Pb212-based ARTs with 3B Pharmaceuticals’ expertise in peptide radioligand therapy discovery. Read more here: https://t.ly/wJyJ0 #Radiopharmaceuticals #Biotech #NuclearMedicine #Oncology
ARTBIO
生物技术研究
Cambridge，Massachusetts 7,627 位关注者
Empowering patient-centric advances in cancer care
关于我们
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
- 网站
-
www.artbio.com
ARTBIO的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
地点
ARTBIO员工
动态
-
ARTBIO转发了
Check out this job at ARTBIO: CDMO Tech Transfer Lead
-
The ARTBIO team is excited to be attending several upcoming events in the coming weeks, including the William Blair Conference, the ICPO Foundation-International Centers for Precision Oncology Theranostics Summit, and the 2024 Jefferies London Healthcare Conference! ARTBIO Chief Scientific Officer Nick Pullen will be speaking at the ICPO Summit with a first disclosure of pre-clinical data underwriting the superiority of alpha emission in a bone metastasis Prostate Cancer model, as well as clinical data from a Ph0 evaluation of AB001. ARTBIO Chief Executive Officer Emanuele Ostuni will be joining Andy Hsieh for a fireside chat as part of the William Blair’s Innovator Series: Radiopharmaceuticals, discussing ARTBIO’s vision for Pb212-based alpha radioligand therapies and the progress the company has made since its inception. We look forward to insightful discussions and sharing the latest updates about our approach to #Alpha #Radioligand #Therapies (#ART). Find out more about our unique approach at https://artbio.com/ #WilliamBlair #JefferiesHealthcare #RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine
-
ARTBIO转发了
Excited about alpha radioligand therapies and peptide science? ARTBIO is hiring! #radioligandtherapy #peptidechemistry #peptides #SAR #drugdevelopment
-
Principal Investigator Dr.?Kjetil Berner?from?Oslo University Hospital?will be presenting early clinical data on ARTBIO’s lead program, AB001, a PSMA-targeted 212Pb #Alpha #Radioligand #Therapy for metastatic castration resistant prostate cancer (#mCRPC), at the 2024 European Multidisciplinary Congress on Urological Cancers (#EMUC24). ? The poster presentation highlights data from the Phase 0 imaging study of AB001. Gamma camera imaging following a 212Pb AB001 microdose showed tumor targeting and promising biodistribution. This early clinical research could lead to more treatment options for patients with prostate cancer in the future. View the poster here: https://lnkd.in/et7_p356 ? Be sure to stop by to learn how we are redefining cancer care by developing a new class of #Alpha #Radioligand #Therapies (#ARTs) based on the ideal isotope #Pb212. ? #RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine #Oncology #ProstateCancer
-
ARTBIO is excited to announce that we have been nominated for the New England Venture Capital Association Emerging Life Sciences Company at the 12th Annual Nevy Awards! We are honored to be recognized with the other companies and breakthroughs of New England that are reshaping industries and driving the innovation economy forward. At ARTBIO, our commitment to innovation and patients drives us forward as we harness the power of #Alpha #Radioligand #Therapies (#ARTs) to set new standards in #NuclearMedicine. Learn more here: https://lnkd.in/e548JKAk #NEVYs24 #NEVYsSurvivor #NEVCA #Innovation
The tribal councils have spoken…The #NEVYs24 nominees are here! We're thrilled to reveal the nominees for the 12th Annual NEVYs Awards! In this "Survivor" themed celebration of New England’s startup ecosystem, 60+ top-tier companies have made it through fierce competition to earn their place across five “tribes” that represent the region's best in Tech, Tough Tech, Healthcare IT, Life Science, and MedTech. Each nominee has proven their resilience, innovation, and expertise to “Outwit, Outplay, and Outlast” in 2024—and we can't wait to celebrate these innovators on December 5th. Ready to meet the nominees? Read the official press release for all the details! https://bit.ly/4huDoU7 #NEVYsSurvivor #NEVCA #Innovation #NewEnglandStartups
New England Venture Capital Association Announces Nominees for the 12th Annual NEVY Awards
New England Venture Capital Association，发布于领英
-
ARTBIO转发了
The group I'm in at ARTBIO is growing! We are looking for a biochemist/biophysicist with some plate based assay experience (SPR or ITC experience are a plus)! Reach out if you're interested or know someone that might be a good fit! https://lnkd.in/ePUZqZVk
-
We are delighted to announce that ARTBIO has entered into a master supply agreement with Thor Medical ASA. Thor Medical will supply #thorium (Th-228) to ARTBIO for the manufacturing of Pb212 through our proprietary AlphaDirect technology to support the development of our pipeline of novel #Alpha #Radioligand #Therapies. Learn more: https://shorturl.at/l9GXl Thor Medical is pioneering methods to recover Th228 from existing material stockpiles rather than manufacturing it by irradiating other materials.?We look forward to working closely with them in our Oslo laboratories, not far away from their production site. #NuclearMedicine #RadioligandTherapy #Radiopharmaceuticals #Biotech #ProstateCancer #ARTs
Thor Medical signs first supply agreement as key building block to commercial scale production???? Today marks a significant step forward in enabling next-generation cancer therapies with the announcement of the strategic long-term supply agreement of Thorium-228 to ARTBIO: ? 5-years of supply agreement, representing revenues for Thor Medical of up to NOK 200 million over the term ? Potential to increase deliveries and revenues up to NOK 400 million, conditional on certain milestones including production ramp-up and market development "Securing strategic supply agreements are an important prerequisite for a positive investment decision for our planned commercial production plant. The agreement with ARTBIO represents significant progress in the efforts to commercialize large-scale production and supply of the world's purest radionuclides from the natural decay of thorium to help transform cancer care", says Jasper C. Kurth, CEO of Thor Medical. The Thorium-228 will be produced at the planned commercial-scale facility at Her?ya Industripark AS, where Thor Medical expects to make the final investment decision in Q1 2025. The company assumed pilot production at the same site earlier this month. “A stable and reliable supply of high-quality isotopes is key to the successful development of our pipeline and partnering with Thor Medical is a valuable next step in building out the supply chain that supports our pipeline of novel alpha radioligand therapies, including our lead asset AB001 for the treatment of prostate cancer”, says Emanuele Ostuni, CEO of ARTBIO. Check out the full release ?? https://lnkd.in/d_D5iZmx #alphaemitters #alpharadioligandtherapies #art #precisioncancertreatment
-
-
The European Association of Nuclear Medicine (EANM) Annual Congress kicks off this Saturday and we’re thrilled to be attending! Join us as we explore the latest advancements in #NuclearMedicine, share insights with industry leaders, and connect with fellow innovators. Together, we can shape the future of patient care and drive meaningful change in the field. Stay tuned for updates from the event! #EANM24 #RadioligandTherapy #Radiopharmaceuticals #Biotech Emanuele Ostuni | Conrad Wüller | ? Philippe Dasse ? ? | Daniel Rossetto | Phil Ruis | Vicki Jardine | Ivana Galetic | Mohana Suppiah-Coll | Tanja Aarvak | Elisa Fiorito, Ph.D. | Vilde Yuli Stenberg | Joshua Needham-Clark | Rosa Greasley | Jordi Vall-llossera
-
Please join us in welcoming Amra Demirovic as Chief Human Resources Officer! Amra brings extensive experience in human resources and a proven track record of fostering inclusive workplace cultures. Amra comes to us from BeiGene, where she led HR for Europe & New Markets. Prior to that, she held key HR positions at Novartis. Amra loves sports and exploring the world with her son. Welcome to the team, Amra! #nuclearmedicine #radioligandtherapy #radiopharmaceuticals #biotech #team